<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="3EDAA8C1-0007-A6FA-C13B-B3D16D9C79F6" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Human prescription drug label" />
<title ID="INV-02ea0f77-4819-4621-b95a-2a5f76148d0d" mediaType="text/x-hl7-title+xml">4% BranchAmin&#174; (Branched Chain Amino Acid)
        Injection<br />Pharmacy Bulk Package<br />Not for Direct Infusionin Viaflex&#174; Plastic Container</title>
<effectiveTime value="20051214" />
<availabilityTime />
<setId root="1bcf8fc4-97e1-4472-9f02-56cfec5f30ae" />
<versionNumber value="1" />
<author>
<time />
<assignedEntity>
<representedOrganization>
<name>Baxter Healthcare Corporation</name>
</representedOrganization>
</assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="D256FAE7-DFA2-B775-72EA-F5606254ACC0" />
<effectiveTime value="20051214" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0338-0477" codeSystem="2.16.840.1.113883.6.69" />
<name>BranchAmin</name>
<formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION" />
<activeIngredient>
<quantity>
<numerator unit="g" value="13.68">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="13.68" />
</numerator>
<denominator unit="L" value="1">
<translation code="C48505" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LITER" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Leucine</name>
<activeMoiety>
<activeMoiety>
<code code="GMW67QNF9C" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Leucine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="13.68">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="13.68" />
</numerator>
<denominator unit="L" value="1">
<translation code="C48505" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LITER" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Isoleucine</name>
<activeMoiety>
<activeMoiety>
<code code="04Y7590D77" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Isoleucine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<activeIngredient>
<quantity>
<numerator unit="g" value="12.23">
<translation code="C48155" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GRAM" value="12.23" />
</numerator>
<denominator unit="L" value="1">
<translation code="C48505" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LITER" value="1" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Valine</name>
<activeMoiety>
<activeMoiety>
<code code="HG18B9YRS7" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>Valine</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>leucine, isoleucine and valine</name>
</genericMedicine>
</asEntityWithGeneric>
<asContent>
<quantity>
<numerator unit="mL" value="500">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="500" />
</numerator>
<denominator value="1">
<translation codeSystem="2.16.840.1.113883.3.26.1.1" value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0338-0477-03" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG" />
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section ID="INV-b39a5b35-9ffb-49a4-8a13-ab1fe85a22f3">
<id root="46C2B388-BF0C-B27B-5575-DE7D8F23D1BA" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Description Section" />
<title ID="INV-24d3c77d-ddd3-45ff-bb3a-c6b3dfc0cc19" mediaType="text/x-hl7-title+xml">DESCRIPTION</title>
<text><paragraph ID="INV-7ebdecdc-f15d-4166-97ca-c8a565f30f3a">4% BranchAmin&#174;
                            (Branched Chain Amino Acid) Injection is a sterile, nonpyrogenic
                            solution of the essential amino acids isoleucine, leucine, and valine
                            provided in a Pharmacy Bulk Package. A Pharmacy Bulk Package is a
                            container of a sterile preparation for parenteral use that contains many
                            single doses. The contents are intended for use in a pharmacy admixture
                            program and are restricted to the preparation of admixtures for
                            intravenous infusion.</paragraph><paragraph ID="INV-29ded223-a12e-4db1-9aac-da9cfdbe7690">The Viaflex&#174;
                            plastic container is fabricated from a specially formulated polyvinyl
                            chloride (PL 146&#174; Plastic). Exposure to temperatures above 25&#176;C/77&#186;F
                            during transport and storage will lead to minor losses in moisture    content. Higher temperatures lead to greater losses. It is unlikely that
                            these minor losses will lead to clinically significant changes within
                            the expiration period. The amount of water that can permeate from inside
                            the container into the overwrap is insufficient to affect the solution
                            significantly. Solutions in contact with the plastic container can leach
                            out certain of its chemical components in very small amounts within the
                            expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
                            per million. However, the safety of the plastic has been confirmed in
                            tests in animals according to USP biological tests for plastic
                            containers as well as by tissue culture toxicity studies.</paragraph><paragraph ID="INV-3d8c0f08-3e3e-4802-b9a5-5243cd26906b">Each 100 mL of 4%
                            BranchAmin&#174; (Branched Chain Amino Acid) Injection contains:</paragraph><table frame="border" width="500.00pt"><col align="left" width="250.00pt" />
<col align="left" width="250.00pt" />
<col align="left" />
<tbody valign="top">
<tr valign="bottom"><td align="left" valign="bottom">Amino Acids</td><td align="left" valign="bottom">4g</td><td align="left" valign="bottom" /></tr>
<tr valign="top"><td align="left" valign="top">Total Nitrogen</td><td align="left" valign="top">443 mg</td><td align="left" valign="top" /></tr>
<tr valign="top"><td align="left" valign="top">pH</td><td align="left" valign="top">6.0 (5.0 to 7.0)</td><td align="left" valign="top" /></tr>
<tr valign="top"><td align="left" valign="top">Osmolarity (calc.)</td><td align="left" valign="top">316 mOsmol/L</td><td align="left" valign="top" /></tr>
<tr valign="top"><td align="left" valign="top" /><td align="left" valign="top" /><td align="left" valign="top" /></tr>
<tr valign="top"><td align="left" valign="top" /><td align="left" valign="top" /><td align="left" valign="top" /></tr>
</tbody>
</table></text>
<effectiveTime value="20051214" />
<component>
<section ID="INV-0b3a1073-ccb2-4b18-9c18-3994f75f7a9c">
<id root="904E7ADD-8F45-47E1-60EC-6453563D5CC0" />
<title ID="INV-889e8419-7b35-4b9d-a691-f68c879c223c" mediaType="text/x-hl7-title+xml">Essential Amino
                                Acids</title>
<text><renderMultiMedia referencedObject="MM-5cc8e49f-15f7-4246-ab8b-a8be72ed9f10" /></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<observationMedia ID="MM-5cc8e49f-15f7-4246-ab8b-a8be72ed9f10">
<value mediaType="image/jpeg"><reference value="spl-4-BranchedChainAminoAcid-PL146-figure-1.JPG" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section ID="INV-f6dc2d19-c216-46a1-be92-bab02817aa28">
<id root="938D01C5-2EFF-C81E-141E-D8E068D873E7" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Clinical Pharmacology Section" />
<title ID="INV-3f7e0473-01e1-4ad8-9033-078369180c61" mediaType="text/x-hl7-title+xml">CLINICAL PHARMACOLOGY</title>
<text><paragraph ID="INV-8e695cbb-d139-4842-9fec-1f612b291ff1">4% BranchAmin&#174;
                            (Branched Chain Amino Acid) Injection, when appropriately admixed with a
                            complete amino acid injection, such as Travasol&#174; (Amino Acid) Injection,
                            with or without a concentrated calorie source, provides total parenteral
                            nutrition for the severely compromised patient. A common effect of
                            severe stress conditions is depletion of branched chain amino acids.
                            Enriching the standard amino acid solution in TPN with additional
                            branched chain amino acid results in their repletion. </paragraph><paragraph ID="INV-f89a7c25-5fbb-4486-b62d-8637357c469a">See package insert
                            of the complete amino acid solution for additional information such as
                            Contraindications, Warnings and Precautions pertinent to that drug and
                            general total parenteral nutrition therapy.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-fd1ce56e-fac1-446c-b417-a0a1260e4a94">
<id root="F8B70F3D-13C8-87EE-A785-C8B913FA755B" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Indications and Usage Section" />
<title ID="INV-14a84ffd-49df-44a9-948e-17df2ac116ce" mediaType="text/x-hl7-title+xml">INDICATIONS AND USAGE</title>
<text><paragraph ID="INV-81b38a6b-f7c2-479a-be13-4aca285633f6">4% BranchAmin&#174;
                            (Branched Chain Amino Acid) Injection, when appropriately admixed with a
                            complete amino acid injection such as Travasol&#174; Injection, is indicated
                            as an adjunct in offsetting of nitrogen loss or in the treatment of
                            negative nitrogen balance in patients where (1) the alimentary tract                            cannot or should not he used; (2) gastrointestinal absorption of protein
                            is impaired; or (3) nitrogen homeostasis is substantially impaired as
                            with severe trauma or sepsis. Dosage, route of administration and    concomitant infusion of nonprotein calories are dependent on various
                            factors such as nutritional and metabolic status of the patient,
                            anticipated duration of parenteral nutritional support and vein
                            tolerance. See <linkHtml href="#INV-800a6038-7522-42a9-947f-f21dc85c14bb">Dosage and Administration</linkHtml> for additional
                        information.</paragraph></text>
<effectiveTime value="20051214" />
<component>
<section ID="INV-49a0ffda-6b7d-4fa3-b55f-4fa3588dd551">
<id root="8ABCD7F1-7141-A8B3-A262-D72B3923CE46" />
<title ID="INV-5e9f06ce-092f-40ee-98a8-4f7ecdc3f318" mediaType="text/x-hl7-title+xml">Central Vein
                                Administration: </title>
<text><paragraph ID="INV-d9b4f11f-38b8-46b6-bae4-c0ce380b9208">Central
                                    venous infusion should be considered when amino acid solutions
                                    are to be admixed with hypertonic dextrose to promote protein
                                    synthesis such as for hypercatabolic or depleted patients or
                                    those requiring long-term parenteral nutrition.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-68105afc-d0eb-4096-b2fa-3c6fedb0ddea">
<id root="D63DA11B-FFB3-2ECA-27ED-670F956C5007" />
<title ID="INV-0375ded9-00c9-4307-87b7-296da0732e36" mediaType="text/x-hl7-title+xml">Peripheral Vein
                                Administration: </title>
<text><paragraph ID="INV-2a398d44-185d-4a69-8bd9-f8306b9fe9eb">For
                                    patients in whom the central venous route is not indicated,
                                    amino acid solutions mixed with low dextrose concentrations may
                                    be infused by peripheral vein when supplemented with or without
                                    fat emulsion.</paragraph><paragraph ID="INV-7feb4c83-1daf-41b4-b7ed-c870b1318e54">Enrichment
                                    of the TPN solution with the branched chain amino acid additive
                                    is recommended until the patient exhibits a marked reduction in
                                    the clinical signs and symptoms of metabolic stress, usually 7
                                    to 14 days.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-f6d3eec9-a87e-480c-99c1-ca7b77eb98dd">
<id root="2D817D4E-C095-A25B-5661-0DA3418B06C0" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Contraindications Section" />
<title ID="INV-a4a1c152-7b26-4dab-b709-deb3e3cadadd" mediaType="text/x-hl7-title+xml">CONTRAINDICATIONS</title>
<text><paragraph ID="INV-f1dd73ac-a4fd-4650-b783-9493ac6c8ca3">4% BranchAmin&#174;
                            (Branched Chain Amino Acid) Injection should not be administered to
                            patients with inborn errors of metabolism, especially those involving
                            branched chain amino acids such as maple syrup urine disease, isovaleric
                            acidemia, etc.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-1e6f5090-609c-4415-ac6b-e90c0c86324a">
<id root="345647D2-A186-0A40-E907-EC638C16753B" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Warnings Section" />
<title ID="INV-75e17ca3-b1c6-483b-b48f-6f38d942253d" mediaType="text/x-hl7-title+xml">WARNINGS</title>
<text><paragraph ID="INV-e125b691-b402-4181-a8ec-6d55b9bbbc48"><content styleCode="bold">This injection is for compounding only, not
                                for direct infusion.</content></paragraph><paragraph ID="INV-d12999c0-f240-4190-b4f7-c60a5376ad12">Supplementation of
                            branched chain amino acids should occur only with concomitant
                            administration of solutions having complete amino acid profiles and
                            energy substrates designed to meet minimal protein and calorie
                            requirements.</paragraph><paragraph ID="INV-2675200c-0109-433c-a021-cef4ecd3c92c">WARNING: This
                            product contains aluminum that may be toxic. Aluminum may reach toxic
                            levels with prolonged parenteral administration if kidney function is
                            impaired. Premature neonates are particularly at risk because their
                            kidneys are immature, and they require large amounts of calcium and
                            phosphate solutions, which contain aluminum.</paragraph><paragraph ID="INV-90aa96b2-15ff-4878-b64a-2f42543b22e9">Research indicates
                            that patients with impaired kidney function, including premature
                            neonates, who receive parenteral levels of aluminum at greater than 4 to
                            5 &#181;g/kg/day accumulate aluminum at levels associated with central
                            nervous system and bone toxicity. Tissue loading may occur at even lower
                            rates of administration.</paragraph><paragraph ID="INV-4c4aa3fa-05de-42cf-b9cf-0adcd2c7f603">Hyperammonemia has
                            been reported to occur in infants receiving various amino acid
                            supplementation regimens. Blood ammonia monitoring may be prudent in 4%
                            BranchAmin&#174; infusions.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-e8d62ea6-92b0-44da-8353-105c8917ee31">
<id root="2E43D7D6-0E9D-9050-6E88-F1717F042091" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="General Precautions Section" />
<title ID="INV-14a1d4e0-f849-4480-aa10-b0ddf773afe8" mediaType="text/x-hl7-title+xml">GENERAL PRECAUTIONS</title>
<text><paragraph ID="INV-b253dc2a-419e-43fb-a620-a5928b505462">The concentration
                            of 4% BranchAmin&#174; (Branched Chain Amino Acid) Injection is close to the
                            solubility limits of the components. If exposed to cold, crystals may
                            form. Redissolve any formed crystals by warming to 50&#186;C. Note: Protect
                            closure from contamination. Do not admix until solution is clear and
                            free of visible particulates.</paragraph><paragraph ID="INV-9c0381a1-3075-439e-a9ae-faff29f7053d">Drug product
                            contains no more than 25 &#181;g/L of aluminum.</paragraph></text>
<effectiveTime value="20051214" />
<component>
<section ID="INV-3c94cf84-35d0-4918-80c6-0b4a03527295">
<id root="99EC37D1-A5C7-C29D-C7AF-8769E4453EE7" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Carcinogenesis and Mutagenesis and Impairment of Fertility Section" />
<title ID="INV-c924fff8-47e8-4696-9b30-dadd7af87eba" mediaType="text/x-hl7-title+xml">Carcinogenesis and
                                Mutagenesis and Impairment of Fertility</title>
<text><paragraph ID="INV-2304c8a1-c495-4167-8ae7-a3f19430a87e">Studies
                                    with 4% Branchamin&#174; (Branched Chain Amino Acid) Injection have
                                    not been performed to evaluate carcinogenic potential, mutagenic
                                    potential, or effects on fertility.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-ab305083-16fb-4926-8af4-cf9a967fee06">
<id root="DC6F2C43-55F4-2985-D16E-4CDE44F58DD5" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="PREGNANCY" />
<title ID="INV-d3758b95-36da-48e8-a8d9-5f49b8ecaea3" mediaType="text/x-hl7-title+xml">Pregnancy</title>
<text />
<effectiveTime value="20051214" />
<component>
<section ID="INV-909edd0d-1d4f-4662-bb5d-480369827e20">
<id root="91B8723F-C154-E2DC-F64B-2884E7145F9F" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="TERATOGENIC EFFECTS SECTION" />
<title ID="INV-9bc9c2fa-133c-4b1a-8f75-c2c640f3b7cc" mediaType="text/x-hl7-title+xml">Teratogenic
                                        Effects</title>
<text />
<effectiveTime value="20051214" />
<component>
<section>
<id root="27616644-CBF1-34D7-F891-20DDE0828438" />
<title ID="INV-f317b7e2-d132-41d2-a1b9-cb8a0c5d44dc" mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text><paragraph ID="INV-7fdffe95-d82f-4444-9265-57672939f131">Animal reproduction studies have not been
                                                  conducted with 4% BranchAmin&#174; (Branched Chain
                                                  Amino Acid) Injection. It is also not known
                                                  whether 4% BranchAmin&#174; (Branched Chain Amino
                                                  Acid) Injection can cause fetal harm when
                                                  administered to a pregnant woman or can affect
                                                  reproduction capacity. 4% BranchAmin&#174; (Branched
                                                  Chain Amino Acid) Injection should be given to a
                                                  pregnant woman only if clearly
                                                needed.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-c90c83d0-7ceb-40f6-80be-10e83f041fe1">
<id root="ADE0E3E2-82EB-90E9-F700-30A36C715A27" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nursing Mothers Section" />
<title ID="INV-d80b1714-c428-4c1f-85b5-a9333626c6bf" mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph ID="INV-46ec3a3b-c689-4d7a-a225-80e33fc72784">It is not
                                    known whether this drug is excreted in human milk. Because many
                                    drugs are excreted in human milk, caution should be exercised
                                    when 4% BranchAmin&#174; (Branched Chain Amino Acid) Injection is
                                    administered to a nursing mother.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-5fbaf928-b6a2-4b3b-b625-8db5466c0583">
<id root="698A5B42-301D-C969-A52B-FB19CFBEC058" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Pediatric Use Section" />
<title ID="INV-fb4199d6-a410-4199-8cfb-71853234b28f" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph ID="INV-1e171b07-d2e7-4c3d-a0c0-a7922e8d12e6">The safety
                                    and effectiveness of 4% BranchAmin&#174; (Branched Chain Amino Acid)
                                    Injection in pediatric patients have not been established by
                                    adequate and well-controlled trials.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-120ebd60-52cf-4916-994b-f0d793ebe9a5">
<id root="9D87EC7D-52E6-66A4-AED0-9BB315A9F392" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Geriatric Use Section" />
<title ID="INV-83ac2fd4-0007-4da1-bd6b-951f2652e1cc" mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text><paragraph ID="INV-c20f9537-9139-4c34-b5ab-bd40aae7d18b">Clinical
                                    studies of 4% BranchAmin&#174; (Branched Chain Amino Acid) Injection
                                    did not include sufficient numbers of subjects aged 65 and over
                                    to determine whether they respond differently from other younger
                                    subjects. Other reported clinical experience has not identified
                                    differences in responses between the elderly and younger
                                    patients. In general, dose selection for an elderly patient
                                    should be cautious, usually starting at the low end of the
                                    dosing range, reflecting the greater frequency of decreased
                                    hepatic, renal, or cardiac function, and of concomitant disease
                                    or drug therapy.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
</section>
</component>
<component>
<section ID="INV-f9657a46-a0ae-4b18-b19f-a46db7b3d1c3">
<id root="6C4E757B-7BEC-5710-62F7-7146FCD6DCBD" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Adverse Reactions Section" />
<title ID="INV-e50ea9b8-74a2-41d2-9a85-12071e081df9" mediaType="text/x-hl7-title+xml">ADVERSE REACTIONS</title>
<text><paragraph ID="INV-333b45ab-b5cb-456f-b168-31499d7b03d2">None
                        known</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-ef02a0e5-3920-4f8c-b9f8-eb12888a9169">
<id root="7A600C5D-7721-22D7-E193-1E4B6E86D205" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Dosage and Administration Section" />
<title ID="INV-f3b4bde9-cbd4-4613-a668-881d0869baee" mediaType="text/x-hl7-title+xml">DOSAGE AND ADMINISTRATION</title>
<text><paragraph ID="INV-800a6038-7522-42a9-947f-f21dc85c14bb">Clinical studies
                            have shown that stressed patients can safely utilize up to 1.4 g/kg/day
                            of a 50% branched chain amino acid supplemented solution. However, the
                            total daily dose of the branched chain amino acid supplemented solutions
                            depends upon the judgement of the physician based upon the patient's
                            metabolic requirement, branched chain amino acid deficits and clinical
                            response.</paragraph><paragraph ID="INV-0aecffdc-0063-4f1f-a78c-50793a2ffd1d">Parenteral drug
                            products should be inspected visually for particulate matter and
                            discoloration prior to administration whenever solution and container
                            permit. Use of a final filter is recommended during administration of
                            all parenteral solutions where possible.</paragraph><paragraph ID="INV-21ea957a-4f26-4a51-b5f5-4d2d3d909bdd"><content styleCode="bold">Do not administer unless solution is clear and
                                seal is intact.</content></paragraph><paragraph ID="INV-31cd8fe0-3c6c-4702-9d63-7fa98814ff72">For dosage and
                            administration of concomitantly administered solutions, reference should
                            be made to the specific product information pertinent to that drug.</paragraph><paragraph ID="INV-072a0406-12df-4d38-95b8-2027b091b8c9">Care should be
                            exercised to insure the maintenance of proper levels of serum potassium.
                            Quantities of 60 to 180 mEq of potassium per day have been used with
                            adequate clinical effect. All serum electrolytes should be monitored
                            frequently and electrolyte requirements individualized.</paragraph><paragraph ID="INV-94fea894-f03a-4da5-bc76-005948d899cc">Usual
                            administration of 4% BranchAmin&#174; (Branched Chain Amino Acid) Injection
                            is as a supplement to parenteral nutrition solutions to achieve an amino
                            acid solution which is approximately 50% w/w branched chain amino acid.
                            (One method for achieving this ratio is the admixture of two volumes of
                            4% BranchAmin&#174; (Branched Chain Amino Acid) Injection at 4 g/100 mL
                            concentration with one volume of an amino acid solution of 8 to 10 g/100
                            mL concentration.) The supplemental amino acid mixture is administered
                            in combination with energy substrates to provide at least 35 kcal/kg
                            ideal body weight as nonprotein calories.</paragraph><paragraph ID="INV-ae138dda-97c3-45cf-8a3a-d3f86afab836">The treatment
                            regimen should be discontinued when the patient exhibits a marked
                            reduction in the clinical manifestations of metabolic stress, usually 7
                            to 14 days.</paragraph><paragraph ID="INV-9b054519-148b-405d-9b8b-3f3822f4c917">4% BranchAmin&#174;
                            (Branched Chain Amino Acid) Injection in the Pharmacy Bulk Package is
                            intended for use in the preparation of sterile, intravenous admixtures.
                            Additives may be incompatible with the fluid withdrawn from this
                            container. Complete information is not available. Those additives known
                            to be incompatible should not be used. Consult with pharmacist, if
                            available. When compounding admixtures, use aseptic technique. Mix
                            thoroughly. Do not store any unused portion of 4% BranchAmin&#174; (Branched
                            Chain Amino Acid) Injection.</paragraph></text>
<effectiveTime value="20051214" />
<component>
<section ID="INV-5ddb6ed7-185a-40cb-aafd-35d36b2e3282">
<id root="C4940EF3-CD12-637A-B062-3400CFB84FDB" />
<title ID="INV-640ecb26-3a40-46ca-bc2f-cd9f45007758" mediaType="text/x-hl7-title+xml">Directions for Use
                                of Viaflex<content styleCode="bold">&#174;</content> plastic Pharmacy
                                Bulk Package container</title>
<text />
<effectiveTime value="20051214" />
<component>
<section ID="INV-3c732f7d-866a-4923-8b6b-dcdee7db033d">
<id root="8478F90C-AB41-14D9-6217-627027F96C41" />
<title ID="INV-2c437423-40fe-4ffe-82fb-41231008ba6f" mediaType="text/x-hl7-title+xml">To Open</title>
<text><paragraph ID="INV-62ff7f77-dcfd-4997-8763-c3ed19ffa430">Tear overpouch down side at slit and remove solution
                                            container. Some opacity of the plastic due to moisture
                                            absorption during the sterilization process may be
                                            observed. This is normal and does not affect the
                                            solution quality or safety. The opacity will diminish
                                            gradually. Check for minute leaks by squeezing inner bag
                                            firmly. If leaks are found, discard solution as
                                            sterility may be impaired. </paragraph><paragraph ID="INV-73b59e84-ffb7-4708-9d30-76336ff3e1d1">For
                                            compounding only, not for direct infusion.</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
<component>
<section ID="INV-d828bf21-149b-475c-8bc8-b70b59be1807">
<id root="83D9BA9E-CAA7-25B6-073A-37CD298C1DDC" />
<title ID="INV-0474e9dd-983b-4d12-8fe0-f1b50d0689d0" mediaType="text/x-hl7-title+xml">Preparation
                                        for Admixing</title>
<text><list listType="ordered" styleCode="Arabic"><item>The Pharmacy Bulk Package is to be used only in a
                                                suitable work area such as a laminar flow hood (or
                                                an equivalent clean air eompounding area).</item><item>Suspend container from eyelet support. </item><item>Remove plastic protector from outlet port at
                                                bottom of container. </item><item>Attach solution transfer set. Refer to complete
                                                directions accompanying set. Note: The closure shall
                                                be penetrated only one time with a suitable sterile
                                                transfer device or dispensing set which allows
                                                measured dispensing of the contents. </item><item>Viaflex&#174; containers should not be written on
                                                directly since ink migration has not been
                                                investigated. Affix accompanying label for date and
                                                time of entry. </item><item>Once container closure has been penetrated,
                                                withdrawal of contents should be completed without
                                                delay. After initial entry, maintain contents at
                                                room temperature (25&#186;C/77&#186;F) and dispense within 4
                                                hours.</item></list></text>
<effectiveTime value="20051214" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section ID="INV-f93b2a60-46fe-40f1-bc02-2b1dd41c6056">
<id root="F83BA10B-2D7C-80CF-EB4F-276C3D1F05F1" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="How Supplied Section" />
<title ID="INV-bed6e47a-7c33-444e-a575-6c51ab100803" mediaType="text/x-hl7-title+xml">HOW SUPPLIED</title>
<text><paragraph ID="INV-9dd78048-b98f-4fc9-a528-0c7c4052d194">4% BranchAmin&#174;
                            (Branched Chain Amino Acid) Injection is available in a Viaflex&#174; plastic
                            Pharmacy Bulk Package container as shown below.</paragraph><paragraph ID="INV-8a31c2cc-458f-4b97-b87a-1f5c4bccd426">2B6153 500 mL NDC
                            0338-0477-03</paragraph><paragraph ID="INV-ca01f210-319d-44b2-8be2-89a18e6233fd">Exposure of
                            pharmaceutical products to heat should be minimized. Avoid excessive
                            heat. Protect from excessive cold or freezing. It is recommended the
                            product be stored at room temperature (25&#186;C/77&#186;F).</paragraph><paragraph ID="INV-aa06aa27-89af-493c-899a-53fe3d0e6601"><content styleCode="bold">Baxter Healthcare Corporation</content></paragraph><paragraph ID="INV-9db27535-b947-47f4-afc8-ee7568991c25">Clintec Nutrition
                            Division </paragraph><paragraph ID="INV-0775583a-6759-4646-859e-1dd40dafde4d">Deerfield, IL 60015
                            USA </paragraph><paragraph ID="INV-ccabbd8f-03e6-4343-aef0-8db853160006">Printed in
                        USA</paragraph></text>
<effectiveTime value="20051214" />
</section>
</component>
</structuredBody>
</component>
</document>
